Document is current
Any future updates will be listed below
-
Authors
Fiore, Marco
Barretta, Francesco
Figura, Costanza
Radaelli, Stefano
Colombo, Chiara
Baia, Marco
Borghi, Alessandra
Di Blasi, Elena
Collini, Paola
Vanzulli, Andrea
Buonomenna, Ciriaco
Greco, Francesca G.
Vigorito, Raffaella
Morosi, Carlo
Sangalli, Claudia
Allajbej, Albina
Sanfilippo, Roberta
Salvatore, Daniela
Pasquali, Sandro
Miceli, Rosalba
Casali, Paolo G.
Stacchiotti, Silvia
Callegaro, Dario
Gronchi, Alessandro https://orcid.org/0000-0002-4703-3534
- License Information
-
More Information
Article History
Received: 17 September 2025
Accepted: 20 November 2025
First Online: 13 December 2025
Disclosure
: Dario Callegaro Firma Prognostica per Pazienti Affetti da Sarcomi Retroperitoneali was a patent beneficiary (Italian patent no. 102024000004447) from 29 February 2024. This is a prognostic transcriptomic signature for patients with retroperitoneal sarcoma. Paolo Casali has no personal conflict of interest. However, the Unit I chair received grants for research from Abbisko Therapeutics Co. Ltd., Advenchen, Ayala Pharmaceuticals, Blueprint, Boehringer Ingelheim, Cogent Biosciences, Daiichi Sankyo, Deciphera, EISAI, Eli Lilly, Epizyme Inc. , Foghorn, Glaxo Smith Kline, HUTCHMED, Immunome, IDRX, Inc. , Inhibrix, Karyopharm, Novartis, PharmaMar, Rain Therapeutic, SpringWorks, Syneos Health. The remaining authors have no conflicts of interest.
